University of Texas's Southwestern Medical Center: Breast Cancer Drug Benefits Broader Group Of Patients, Trial Shows
October 27, 2022
October 27, 2022
DALLAS, Texas, Oct. 27 (TNSjou) -- The University of Texas's Southwestern Medical Center issued the following news release:
* * *
A phase 2 study of talazoparib found that it shrank tumors in breast cancer patients not previously indicated for the treatment
* * *
A drug approved to treat breast cancer patients with mutations in the BRCA1 or BRCA2 genes may also benefit people who have other genetic mutations.
Researchers at UT . . .
* * *
A phase 2 study of talazoparib found that it shrank tumors in breast cancer patients not previously indicated for the treatment
* * *
A drug approved to treat breast cancer patients with mutations in the BRCA1 or BRCA2 genes may also benefit people who have other genetic mutations.
Researchers at UT . . .